Program

PO3-10-10

Uric acid lowering effect and pro-inflammatory cytokine modulation along with enhanced renal transporter activities by K-25, a Yokuininto in an endotoxin-induced renal injury condition

[Speaker] Dal-Seok Oh:1
[Co-author] Seung-Hoon Lee:1, Gunhyuk Park:1, Sung Man Oh:1
1:The K-herb Research Center, Korea Institute of Oriental Medicine, Korea

Background: Prolonged hyperuricemia is associated with kidney disease or gouty arthritis. K-25, a commercially available Yokuininto in Kampo medicine, suppresses obesity in high fat diet-induced obese mice; little is currently known about its known anti-hyperuricemic and anti-inflammatory effects could be applied into the new therapeutic challenge. In this study, we reported that K-25 exerted dual actions on lowering serum uric acid (sUA) levels by blocking pro-inflammatory cytokine activities and inducing uricosuric function with anti-renal injury functions.
Methods: The sUA was measured in potassium oxonate (PO) administered mice. Renal transporter uptake assays were measured by HEK293 cells overexpressing system, MDCKII-BCRP transporter assay and Xenopus oocytes system. Immunoassay was used to detect the molecules (OAT3, GLUT9, XO, NGAL, KIM-1 and IL-1 alpha) in LLC-PK1 cell lines.
Results: K-25 (300 mg/kg) reduced sUA by approximately 44% compared to that of PO-induced mice. Organic anion transporter 3 (OAT3) levels decreased in PO-induced hyperuricemic condition, whereas glucose transporter 9 (GLUT9) transporter levels were markedly increased. However, the condition did not alter the levels of URAT1. K-25 inhibited the lipopolysaccharide (LPS)-induced secretion of interleukin-1 alpha (IL-1 alpha) by approximately 63.2% compared to the LPS-treated macrophages. In addition, 500 and 1,000 mcg/mL K-25 inhibited nitric oxide synthesis by approximately 33.7% and 64.6%, respectively. K-25 inhibited xanthine oxidase (XO) activity as was already known. Furthermore, 10 ng/mL of IL-1 alpha, a pro-inflammatory cytokine, elevated neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule-1 (KIM-1) activities in LLC-PK1 cells. The activities of kidney injury biomarkers, NGAL and KIM-1, were reduced by K-25 approximately 36.9% and 72.1%, respectively.
Conclusions: The present findings demonstrated that Yokuininto lowered sUA through both increased uric acid excretion and decreased uric acid production. Our results may provide a basis for the protection of prolonged hyperuricemia-associated acute kidney injury with traditional uric acid-lowering agents such as Yokuininto.
Advanced Search